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Abstract
Antithymocyte globulin (ATG) is commonly used for graft-vs.-host disease (GVHD) prophylaxis in unrelated donor
allogeneic transplantation (Allo-HSCT). However, its use is still controversial in matched sibling donor (MSD) Allo-HSCT,
notably after reduced intensity conditioning (RIC). ATG dose may inﬂuence the outcome, explaining in part the discordant
conclusions in MSD Allo-HSCT. We, therefore, analyzed the impact of ATG doses in patients with acute myeloid leukemia
in ﬁrst complete remission undergoing RIC Allo-HSCT from a MSD. We analyzed 234 patients from the EBMT registry and
compared outcome according to given ATG dose (high dose: ≥ 6 mg/kg, n= 39 or low dose: < 6 mg/kg, n= 195). No
difference was found in the cumulative incidence of acute (grade 2–4: high dose vs. low dose: 21% vs. 13%, p= 0.334;
adjusted hazard ratio (HR): 1.20, p= 0.712) and chronic GVHD (extensive: high dose vs. low dose: 19% vs. 18%,
p= 0.897; adjusted HR: 1.01, p= 0.980). In contrast, high dose of ATG signiﬁcantly increased the incidence of relapse
(52% vs. 26%, p= 0.011; adjusted HR: 1.31, p= 0.001) leading to impaired outcome (HR progression-free survival (PFS):
1.23, p= 0.002; HR overall survival (OS): 1.17, p= 0.029; HR GVHD and relapse-free survival (GRFS): 1.20, p= 0.005).
We conclude that an ATG dose <6 mg/kg is sufﬁcient for GVHD prophylaxis, while higher doses impair disease control and
outcome.
Introduction
The use of antithymocyte globulin (ATG) as a part of the
conditioning regimen was reported as effective for pro-
phylaxis of graft-vs.-host disease (GVHD) without
increasing the risk of relapse in the setting of unrelated
donor myeloablative allogeneic hematopoietic stem cell
transplantation (Allo-HSCT) [1–4]. However, the role of
ATG for HLA-identical sibling Allo-HSCT is still con-
troversial after reduced intensity conditioning (RIC). A
large CIBMTR analysis suggested that the use of ATG after
RIC reduced the incidence of GVHD but increased the risk
of relapse when a matched sibling donor (MSD) is used,
leading to worse outcome compared with patients who did
not receive any in vivo T-cell depletion [5]. In contrast, the
EBMT comparison, focused on acute myeloid leukemia
(AML) patients undergoing RIC Allo-HSCT from a MSD
in ﬁrst complete remission (CR1), showed that the use of
ATG reduced the incidence of GVHD without increasing
the risk of relapse [6]. These discordant conclusions could
be explained by the different median doses of ATG used, 7
and 5 mg/kg in the CIBMTR and EBMT studies,
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respectively. Thus, we hypothesized that the dose of ATG is
a critical issue and could be a major determinant of outcome
after Allo-HSCT. This was previously suggested in differ-
ent retrospective analyses, but the relative low number of
patients and/or the heterogeneity in baseline characteristics
(donor, graft source, GVHD prophylaxis) did not allow
drawing strong conclusions [7–10]. Here, we investigated
the impact of the ATG dose as part of a RIC regimen on the
outcome of patients transplanted for CR1 AML, in the
speciﬁc setting of MSD.
Materials and methods
Data collection and selection criteria
This retrospective study was performed by the Acute Leu-
kemia Working Party (ALWP) of the European society for
Blood and Marrow Transplantation (EBMT). Patients with
the following criteria were included for this analysis: (1)
ﬁrst Allo-HSCT between January 2000 and February 2013;
(2) AML in CR1; (3) peripheral blood stem cells (PBSC)
from a MSD as graft source; (4) RIC regimen using ATG
(Thymoglobulin); and (5) cyclosporine A (CsA) alone as
post-graft immunosuppression. Patients receiving ex vivo
manipulated graft were excluded. Data were collected using
the EBMT minimum essential data forms and additional
information concerning the dose of ATG was provided
using speciﬁc request forms. Forty-three voluntary EBMT
centers participated in this study (Supplemental File). The
study was approved by the scientiﬁc committee of ALWP
of EBMT, and was conducted in accordance with the
Declaration of Helsinki for clinical research. All patients
gave signed informed consent for data collection and par-
ticipation in retrospective database analyses.
Statistical analyses
Patients who received ATG doses of 6 mg/kg or more
constituted the high-dose group because this corresponds to
more than 2 days of ATG at 2.5 mg/kg/day. The remaining
patients formed the low-dose group. Both high-dose and
low-dose groups were compared according to classical end
points. Acute and chronic GVHD were classiﬁed using the
Glucksberg and Seattle classical scales, respectively [11,
12]. The cumulative incidences of GVHD, relapse (CIR),
and non-relapse mortality (NRM) were estimated using the
Prentice methods, and the Gray test was used for univariate
comparisons [13, 14]. Death from any cause before the
occurrence of GVHD was considered as a competing event
for the incidence of GVHD. Death in CR1 deﬁned the event
for the incidence of NRM and was considered as a com-
peting event for the CIR. The Kaplan–Meier method and
log-rank test were used to calculate and to compare the
progression-free (PFS), overall survivals (OS), and GVHD
and relapse-free survival (GRFS) [15]. In GRFS calculation,
grade 3–4 acute GVHD, extensive chronic GVHD, relapse,
and death were considered as relevant events [16]. All time-
to-event calculations start at the time of Allo-HSCT. All
patients were censored at last contact in the absence of
relevant events. The impact of ATG doses (as continuous
and categorical variable) was evaluated using a multivariate
Cox model adjusted by cytogenetics (adverse vs. other),
time from diagnosis to Allo-HSCT (≤ vs. >6 months), age
at the time of Allo-HSCT (≤ vs. >55 years), RIC regimen
types (busulfan-base vs. other), and transplantation period
(2000–2008 vs. 2009–2013) [17]. Statistical analyses were
computed using R-project 3.2.1 software.
Results
Patient and transplantation characteristics
We analyzed 234 consecutive patients with a median age of
55 years (range: 22–70; Table 1). Forty-one (18%) patients
had unfavorable cytogenetics and 214 (90%) received a
busulfan-based RIC regimen (total busulfan dose of 260
mg/m² or 6.4 mg/kg). ATG was given at the dose of 6 mg/
kg or more to 39 patients (high-dose group), while 195
received lower dose (low-dose group). The median ATG
doses in the high-dose and low-dose groups were 7.5 (6–10)
and 5 (2–5.5) mg/kg, respectively. In the low-dose group,
most of patients received 5 mg/kg of ATG, while only 35
patients (18%) had very low-ATG dose, below 3mg/kg.
The very low-dose group had similar disease risk of relapse
compared with other groups according to cytogenetics (20%
of adverse cytogenetics). Patients in the high-dose group
were more frequently transplanted before 2009 (p= 0.022)
and received slightly more frequently a RIC regimen
without busulfan (p= 0.053). Age, time from diagnosis to
Allo-HSCT, and cytogenetic risk groups were equally dis-
tributed in both high- and low-ATG dose groups.
GVHD and NRM
In the whole cohort, the incidences of grade 2–4 and grade
3–4 acute GVHD at day +100 were 15% and 7%, respec-
tively. No difference was found between the two dose
groups (grade 2–4: high dose vs. low dose: 21% and 13%,
p= 0.334; grade 3–4: high dose vs. low dose: 10% vs. 7%,
p= 0.579; Table 2, Fig. 1a). At 2 years, the cumulative
incidences in all patients of limited+ extensive and exten-
sive chronic GVHD were 40% and 18%, respectively,
without signiﬁcant difference according to ATG dose
(limited+ extensive: high dose vs. low dose: 40% vs. 40%,
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p= 0.824; extensive: high dose vs. low dose: 19% vs. 18%,
p= 0.897; Table 2, Fig. 1b). Among low-dose group
patients, those who received a dose of ATG lower than 3
mg/kg had a trend for higher incidence of chronic GVHD
(54%) compared to those who received a dose between 3
and 5.5 mg/kg (37%, p= 0.054). The cumulative incidences
of NRM on day +100 were 13% and 10% in the high-dose
and low-dose groups, respectively, leading to similar 2-year
NRM (high dose vs. low dose: 15% vs. 14%, p= 0.878;
Table 2, Fig. 2a). Adjusted Cox model conﬁrmed that both
acute (hazard ratio (HR): 1.20, p= 0.712) and chronic (HR:
1.01, p= 0.980) GVHD, as well as NRM (HR: 1.49, p=
0.399) were comparable between both dose groups
(Table 3).
Relapse and survivals
The CIR at 2 years was twofold higher in the high-dose
compared to the low-dose group (52% vs. 26%, respec-
tively, p= 0.011, Table 2, Fig. 2b). This led to signiﬁcantly
shorter PFS (high-dose vs. low-dose, 2-year estimates: 33%
vs. 60%, p= 0.005; Table 2, Fig. 3a) and OS (high-dose vs.
low-dose, 2-year estimates: 49% vs. 64%, p= 0.041;
Table 2, Fig. 3b) in patients receiving high ATG doses. In
addition, GRFS was signiﬁcantly lower in the high-dose
group (high-dose vs. low-dose, 2-year estimates: 28% vs.
50%, p= 0.023; Table 2, Supplement Fig. 1). Among the
low-dose group patients, there was no difference between
those receiving less and more than 3 mg/kg of ATG dose in
CIR (p= 0.100), PFS (p= 0.179), OS (p= 0.289), and
GRFS (p= 0.272). Adjusted multivariate model (Table 3)
showed that the use of high ATG doses (as a continuous
variable) was signiﬁcantly associated with higher CIR (HR:
1.31, p= 0.001) and shorter PFS (HR: 1.23, p= 0.002), OS
(HR: 1.17, p= 0.029), and GRFS (HR: 1.20, p= 0.005). In
contrast, no difference was found in the incidence of both
acute (HR: 0.98, p= 0.856) and chronic (HR: 0.96, p=
0.845) GVHD or NRM (HR: 1.05, p= 0.747). When ana-
lyzing ATG dose as a categorical variable, we found that the
use of ATG ≥ 6 mg/kg was associated with signiﬁcantly
higher CIR, leading to signiﬁcantly shorter PFS and GRFS,
and to a trend for shorter OS (Table 3). Adverse cytoge-
netics was the only other independent factor that was sig-
niﬁcantly associated with higher CIR (HR: 2.71, p< 0.001)
and shorter PFS (HR: 2.83, p< 0.001) and OS (HR: 3.16,
p< 0.001).
Discussion
Our study aimed to evaluate the role of the ATG dose as
part of the conditioning regimen on the outcome after Allo-
HSCT. To deal with confounding factors such as disease
risk, GVHD prophylaxis, conditioning intensity, or donor
and graft source, we focused on patients with CR1 AML
undergoing PBSC RIC Allo-HSCT from a HLA-identical
sibling donor. Patients who received GVHD prophylaxis
other than CSA alone were excluded, on the basis that we
previously reported worse outcome using CSA+MMF in
Table 1 Patient and transplantation characteristics





N % N % N %
N 234 195 39
Age, median
(range)
55 (22–70) 56 (22–70) 55 (39–65) 0.976
Transplantation period
2000–2008 122 52% 95 48% 27 69% 0.022
2009–2013 112 48% 100 51% 12 31%
Time from diagnosis to Allo-HSCT
≤ 6 Months 138 59% 118 60% 20 51% 0.291
> 6 Months 96 41% 77 39% 19 49%
Conditioning regimens
Flu-Bu 214 91% 182 93% 32 82% 0.052
Other 20 9% 13 7% 7 18%
Adverse cytogenetics
No 193 82% 161 82% 32 82% 0.939




38 (2–143) 37 (2–143) 41 (5–123) 0.403
Bu busulfan, Flu ﬂudarabine
Table 2 Univariate analyses of outcome according to the ATG dose
ATG< 6mg/kg ATG ≥ 6mg/kg p
2 y% 95 CI 2 y% 95 CI
Acute GVHD
Grade II–IV 13 8–18 21 7–32 0.334
Grade III–IV 7 3–10 10 0–19 0.579
Chronic GVHD
All grades 40 32–47 40 22–54 0.824
Extensive 18 12–23 19 5–30 0.897
NRM 14 8–18 15 3–26 0.878
CIR 26 20–33 52 33–65 0.011
PFS 60 53–68 33 21–52 0.005
OS 64 57–62 49 35–68 0.041
GRFS 50 43–58 28 17–46 0.023
GVHD graft-vs.-host disease, GRFS GVHD and relapse-free survival,
NRM non-relapse mortality, CIR cumulative incidence of relapse, OS
overall survival, PFS progression-free survival, 2-y% 2-year estima-
tion, 95 CI 95% conﬁdence interval
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this setting [18]. On this cohort of patients receiving ATG-
based RIC regimen, we found low incidences of severe
forms of acute and chronic GVHD (7% and 18%, respec-
tively), supporting the use of ATG as an efﬁcient GVHD
prophylaxis in the setting of MSD Allo-HSCT. This is in
line with a previously reported series of HLA-identical
sibling Allo-HSCT showing 3–11% of grade 3–4 acute
GVHD and 14–27% of extensive chronic GVHD when
ATG is given as GVHD prophylaxis [6, 19–22]. Interest-
ingly, we found no additional advantage using ATG doses
≥6 mg/kg, suggesting that ATG doses below are likely
sufﬁcient for GVHD prophylaxis.
In contrast, ATG doses ≥6 mg/kg were strongly asso-
ciated with an increased incidence of relapse, leading to
worse survivals. A similar conclusion was previously
reported in the setting of unrelated Allo-HSCT [8]. These
results underline the importance of ATG dosage on the
outcome, and may partly explain the discordance between
the conclusions from the CIBMTR and EBMT analyses, in
which the median doses of ATG were 7 and 5 mg/kg,
respectively. Indeed, a worse outcome was observed in
patients receiving ATG in the CIBMTR study, while no
difference was found in the EBMT study [5, 6]. In addition,
high ATG doses may also impair outcome because of
profound immunosuppression leading to higher incidence
of infections. Indeed, we previously reported that high ATG
doses increase the incidence of early CMV reactivations,
while lower doses preserve anti-CMV-speciﬁc T cells [23–
25]. In addition, it was shown that the use of ATG as part of
RIC regimen is associated with signiﬁcantly higher EBV
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Fig. 1 Cumulative incidences of grade II–IV acute (a) and extensive
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Fig. 2 NRM (a) and CIR (b) according to the ATG dose group (Color
ﬁgure online)
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a rituximab preemptive treatment strategy is used (no PTLD
was observed). [26] In a randomized trail evaluating the
impact of ATG-Fresenius on outcome after myeloablative
Allo-HSCT from MSD, no increased incidence of CMV or
EBV reactivation was observed in the ATG arm [27].
This conﬁrms that the use of low-ATG dose does not
strongly impair immunological recovery against both CMV
and EBV.
These results support the need for a ﬁne tuning of ATG
doses to obtain an effective GVHD prophylaxis without
increasing the risk of relapse. On the basis of our data,
we suggest that a total dose of about 5 mg/kg may
represent a good balance, while the use of higher doses
signiﬁcantly increases the incidence of relapse. In contrast,
very low doses of ATG (2.5 mg/kg) were previously
reported as insufﬁcient for GVHD prophylaxis compared
to the 5 mg/kg dose, with ~30% and 70% of acute and
chronic GVHD, respectively [28]. In our series, we found a
trend for higher incidence of chronic GVHD when very low
doses were given (54%, p= 0.054). The low number of
patients receiving less than 3 mg/kg of ATG may explain in
part that statistical signiﬁcance was not reached in our
study.
Taken together, the data suggest that, in the setting of
HLA-identical sibling Allo-HSCT, the use of low doses
(below 6 mg/kg) of ATG does not impair survival.
Furthermore, the advantage of including ATG in GVHD
prophylaxis may help preserving the quality of life after
Allo-HSCT [29]. This aspect was objectively assessed
and supported in a few prospective studies [3, 21]. It is
important to notice that the good balance obtained here with
low-dose Thymoglobulin cannot be translated easily in
different situations. Schleuning et al. reported in the context
of patients with chronic myelogenous leukemia undergoing
bone marrow myeloablative Allo-HSCT from unrelated
donor that higher doses of ATG (Fresenius ≥ 60 mg/kg
total dose) improved survival by reducing acute
GVHD [30].
In conclusion, our results encourage the use of ATG
as an efﬁcient GVHD prophylaxis in RIC preparative
regimen prior to PBSC Allo-HSCT from HLA-identical
sibling donor, and caution against the use of higher doses
(≥ 6 mg/kg), which signiﬁcantly increase the risk of relapse.
At present, this conclusion applies only to patients in CR1
AML using rabbit ATG Thymoglobulin. Different conclu-
sions may be considered in other settings of disease and
donor types, conditioning intensity, and/or ATG formula-
tion. A prospective randomized trial of ATG vs. no ATG in
matched sibling myeloablative Allo-HSCT was recently
published, and also supports the use of ATG (Fresenius) as
an effective GVHD prophylaxis, without impairing disease
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Fig. 3 PFS (a) and OS (b) according to the ATG dose group (Color
ﬁgure online)
Table 3 Multivariate analysis showing the impact of the ATG dose as
a continuous and a categorical variable (< vs. ≥ 6 mg/kg)
ATG dose (continuous) ATG dose ≥ 6 mg/kg
HRa 95 CI p HRa 95 CI p
Acute GVHD 0.98 0.76–1.26 0.856 1.20 0.46–3.09 0.712
Chronic GVHD 0.96 0.63–1.46 0.845 1.01 0.56–1.81 0.980
NRM 1.05 0.80–1.37 0.747 1.49 0.59–3.80 0.399
CIR 1.31 1.12–1.53 0.001 1.85 1.08–3.17 0.024
PFS 1.23 1.08–1.41 0.002 1.74 1.10–2.77 0.019
OS 1.17 1.02–1.35 0.029 1.62 0.98–2.67 0.062
GRFS 1.20 1.01–1.36 0.005 1.64 1.05–2.56 0.028
CIR cumulative incidence of relapse, GVHD graft-vs.-host disease,
GRFS GVHD and relapse-free survival, HR hazard ratio, OS overall
survival, PFS progression-free survival, 95 CI 95% conﬁdence interval
aHR ratio was adjusted by transplantation period, conditioning
regimen, age, cytogenetics, and time from diagnosis to Allo-HSCT
ATG dose in RIC regimen prior MSD Allo-HSCT for AML
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